ライフサイエンスコーパス: Crohn's disease

1 aseptic abscesses, including IBDs (primarily Crohn's Disease).

2 1 and Paneth cell lysozymes in patients with Crohn's disease.

3 everity of gut-associated conditions such as Crohn's Disease.

4 evealed an increased amount in patients with Crohn's disease.

5 restore CD39 along with immunohomeostasis in Crohn's disease.

6 ent of inflammation and might be a result of Crohn's disease.

7 n why patients with XLA are prone to develop Crohn's disease.

8 nia, low-density-lipoprotein cholesterol and Crohn's disease.

9 agement scenarios for ulcerative colitis and Crohn's disease.

10 g colonoscopies (controls) and patients with Crohn's disease.

11 ne diseases such as rheumatoid arthritis and Crohn's disease.

12 active inflammation in patients with colonic Crohn's Disease.

13 wel disease including ulcerative colitis and Crohn's disease.

14 y studies of medical management of pediatric Crohn's disease.

15 emperate phage sequences in individuals with Crohn's disease.

16 that might contribute to the development of Crohn's disease.

17 intestinal biopsies that poses diagnosis of Crohn's disease.

18 tribute to the development of or result from Crohn's disease.

19 ion studies as linked with increased risk of Crohn's disease.

20 ease continuum within ulcerative colitis and Crohn's disease.

21 ivity and predicting outcomes in small bowel Crohn's disease.

22 ed mucosa and associated with fibrostenosing Crohn's disease.

23 be a new option for the treatment of active Crohn's disease.

24 splenic nodules as a first manifestation of Crohn's Disease.

25 CT-P13 to infliximab in patients with active Crohn's disease.

26 rography were consistent with a diagnosis of Crohn's disease.

27 disease, hereditary polyposis syndromes and Crohn's disease.

28 g clinical remission in patients with active Crohn's disease.

29 ecrease the risk of relapse in patients with Crohn's disease.

30 19 might be a viable therapeutic approach in Crohn's disease.

31 erosis, rheumatoid arthritis, psoriasis, and Crohn's disease.

32 bnormal biomarkers typically associated with Crohn's disease.

33 ation) in patients with treatment-refractory Crohn's disease.

34 ally and biologically in the pathogenesis of Crohn's disease.

35 us adverse event was worsening of underlying Crohn's disease.

36 matory diet with statistical significance in Crohn's disease.

37 olonized with a microbiota from a donor with Crohn's disease.

38 the MAT contribute to the "creeping fat" of Crohn's disease.

39 ory diseases, such as ulcerative colitis and Crohn's disease.

40 m are involved in three viral infections and Crohn's disease.

41 activation of fetal transcription factors in Crohn's disease.

42 this modification might contribute to PD and Crohn's disease.

43 to cardiovascular and metabolic diseases and Crohn's disease.

44 d with increased risk of future diagnosis of Crohn's disease.

45 PD) and also to autoimmune disorders such as Crohn's disease.

46 rus as well as in the inflammatory condition Crohn's disease.

47 with ulcerative colitis 4.0, 95% CI 3.4-4.7; Crohn's disease 2.3, 95% CI 1.8-3.0; and IBD unclassifie

48 Of the 17 patients with monogenic Crohn's disease, 35% had abdominal pain, 24% had nonbloo

49 coccus gnavus, a prevalent gut microbe, with Crohn's disease, a major type of inflammatory bowel dise

50 observed in blood samples from patients with Crohn's disease accompany acute inflammation; with treat

51 eted a disease activity questionnaire (short Crohn's Disease Activity (sCDAI) or Patient Simple Clini

52 ed twelve patients (72%) had active disease (Crohn's Disease Activity Index > 150) and 44 patients (2

53 ts (28%) were in clinical remission disease (Crohn's Disease Activity Index < 150).

54 ents with a decrease of 70 points or more in Crohn's Disease Activity Index (CDAI) from baseline to w

55 e Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) of 220-450, with m

56 were correlated with the following indexes: Crohn's disease activity index (CDAI), fCal, serum C-rea

57 Clinical CD activity was measured with the Crohn's Disease Activity Index (CDAI).

58 ree clinical remission at 1 year after HSCT (Crohn's Disease Activity Index [CDAI] <150).

59 imary outcome, defined as an increase in the Crohn's disease activity index score by 70 points or mor

60 ab biosimilar CT-P13 was approved for use in Crohn's disease after clinical comparison with originato

61 on of acquired generalized lipodystrophy and Crohn's disease (AGLCD) featuring a lack of adipose tiss

62 he autophagy gene ATG16L1 is associated with Crohn's disease, an inflammatory bowel disease (IBD), an

63 8% and 0.3% (odds ratio 2.04; 1.59-2.62) for Crohn's disease and 1.3% and 0.7% (odds ratio 1.75; 1.44

64 A total of 91 patients with Crohn's disease and 102 with ulcerative colitis particip

65 Overall, 16 (72.7%) of 22 studies on Crohn's disease and 15 (83.3%) of 18 studies on ulcerati

66 sy specimens from patients with IBD (30 with Crohn's disease and 27 with ulcerative colitis) and 30 p

67 hildren with a new diagnosis of IBD (71 with Crohn's disease and 41 with ulcerative colitis) and 19 c

68 okinetics were measured in six patients with Crohn's disease and evidence of target engagement assess

69 immune cells among associations stronger in Crohn's disease and in gut mucosa among associations str

70 y and specificity in patients with suspected Crohn's disease and in the detection of inflammatory act

71 ommon genetic variant increases the risk for Crohn's disease and leprosy.

72 opment of IBD as a time-dependent covariate, Crohn's disease and no IBD (both vs ulcerative colitis)

73 sociation studies genetically linked IRGM to Crohn's disease and other inflammatory disorders in whic

74 n diseases and systemic disorders, including Crohn's disease and pancreatic cancer.

75 disorders, such as irritable bowel syndrome, Crohn's disease and pancreatitis.

76 has been associated with ulcerative colitis, Crohn's disease and potentially could have links with co

77 ope and Israel, comprising 212 patients with Crohn's disease and treatment-refractory, draining, comp

78 Inflammatory bowel diseases (IBDs) such as Crohn's disease and ulcerative colitis are characterized

79 Crohn's disease and ulcerative colitis are chronic and p

80 Crohn's disease and ulcerative colitis are complex disea

81 Crohn's disease and ulcerative colitis are driven by bot

82 Crohn's disease and ulcerative colitis are heterogeneous

83 Crohn's disease and ulcerative colitis are the two forms

84 sy dataset that included healthy volunteers, Crohn's disease and ulcerative colitis patients.

85 We aimed to identify serum biomarkers of Crohn's disease and ulcerative colitis that can be detec

86 Inflammatory bowel diseases, which include Crohn's disease and ulcerative colitis, affect several m

87 inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, and in 2,4,6-tri

88 nflammatory bowel diseases (IBDs), including Crohn's disease and ulcerative colitis, are associated w

89 ed with inflammatory bowel disease including Crohn's disease and ulcerative colitis, the arthritis re

90 iated with disease activity in patients with Crohn's disease and ulcerative colitis.

91 Inflammatory bowel disease (IBD) includes Crohn's disease and ulcerative colitis.

92 1), 1854 (54.9%) were male, 1923 (57.0%) had Crohn's disease, and 1451 (43.0%) had ulcerative colitis

93 mean age was 15.1 (SD 1.7) years, 69.9% had Crohn's disease, and 30.1% had ulcerative colitis or IBD

94 arrhea (BAD) is common with ileal resection, Crohn's disease, and diarrhea-predominant irritable bowe

95 lymphoma, gastrointestinal stromal tumours, Crohn's disease, and groove pancreatitis are discussed.

96 Half of the patients had Crohn's disease, and half had ulcerative colitis.

97 that are traditional for clinical trials in Crohn's disease, and identify factors that predict benef

98 h the susceptibility to Parkinson's disease, Crohn's disease, and mycobacteria infection.

99 lpha) agents in the management of psoriasis, Crohn's disease, and rheumatoid arthritis.

100 uced in the small intestine of patients with Crohn's disease, and this correlated with lower frequenc

101 for children with undifferentiated colitis, Crohn's disease, and ulcerative colitis.

102 D), which consists of ulcerative colitis and Crohn's disease, are a significant medical burden-70 000

103 hma, atherosclerosis, pulmonary diseases and Crohn's disease as hubs and thus pointing to common infl

104 mmatory bowel diseases (IBDs), in particular Crohn's Disease, aseptic splenic abscesses have been rep

105 c bacteria, including Ruminococcus gnavus, a Crohn's disease-associated pathobiont.

106 These findings indicate that Crohn's disease-associated patterns of DNA methylation o

107 in blood samples of pediatric patients with Crohn's disease at diagnosis and later time points to id

108 ast 3 months, assessed as moderate-to-severe Crohn's disease at screening, defined as a Crohn's Disea

109 atients (aged >=6 years) with active luminal Crohn's disease at the time of first exposure to inflixi

110 ferentially methylated between patients with Crohn's disease (at diagnosis) and controls.

111 164 pediatric patients (1-17 years old) with Crohn's disease (B1 or B2) who participated in a North A

112 Two sisters, initially managed for Crohn's disease based upon clinical, imaging and patholo

113 asmic antibody (ANCA)-associated vasculitis, Crohn's disease, Behcet's disease, eosinophilic granulom

114 e effective treatments for the management of Crohn's disease but treatment failure is common.

115 composition of the intestinal microbiota in Crohn's disease, but its role on skin microbiota is unkn

116 (IBD), that includes ulcerative colitis and Crohn's disease, can affect not only the gastrointestina

117 Crohn's disease causes chronic inflammation in the gastr

118 in patients with anti-TNF-resistant colonic Crohn's disease (cCD) and ulcerative colitis (UC).

119 There were 312 patients diagnosed with Crohn's disease (CD) and 361 with ulcerative colitis (UC

120 truncation in colon biopsy specimens from 16 Crohn's disease (CD) and 6 ulcerative colitis (UC) patie

121 arker for active ileocolonic inflammation in Crohn's disease (CD) and assess its diagnostic performan

122 ed in patients with ulcerative colitis (UC), Crohn's disease (CD) and colorectal cancer (CRC).

123 e been proposed for patients with refractory Crohn's disease (CD) and fistulizing CD, respectively.

124 LCV is a rare dermatologic manifestation of Crohn's disease (CD) and may occur with the onset of the

125 are a frequent complication in patients with Crohn's Disease (CD) and the presence of fibrosis within

126 Although Crohn's disease (CD) and ulcerative colitis (UC) have be

127 d to examine possible symptom profiles among Crohn's disease (CD) and ulcerative colitis (UC) patient

128 Inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), are co

129 mmatory bowel diseases (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are mu

130 ing chronic gastrointestinal inflammation in Crohn's disease (CD) and ulcerative colitis (UC), in hum

131 Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a d

132 onic, relapsing condition with two subtypes, Crohn's disease (CD) and ulcerative colitis (UC).

133 ammatory potential on the risk of developing Crohn's disease (CD) and ulcerative colitis (UC).

134 small intestinal epithelial cells (IECs) in Crohn's disease (CD) exhibit impaired GPX4 activity and

135 Crohn's disease (CD) has been associated with an increas

136 measure endoscopic activity in patients with Crohn's disease (CD) have limitations.

137 ative colitis (UC) and 108 incident cases of Crohn's disease (CD) in patients with microscopic coliti

138 Pathogenesis of Crohn's disease (CD) involves immune and microbial dysre

139 Crohn's disease (CD) is a chronic gastrointestinal disea

140 Crohn's disease (CD) is a chronic relapsing inflammatory

141 Intestinal inflammation in Crohn's disease (CD) is caused by mucosal immune system

142 Crohn's disease (CD) is characterized by an imbalance of

143 ctive control of the inflammatory process in Crohn's disease (CD) is reflected in intestinal mucosal

144 A mysterious feature of Crohn's disease (CD) is the extra-intestinal manifestati

145 etic resonance index of activity (MARIA) for Crohn's disease (CD) is used to assess the activity of l

146 GIB) of 46% (246/536) and definite/suspected Crohn's disease (CD) of 39% (210/536).

147 ment outcomes for ulcerative colitis (UC) or Crohn's disease (CD) patients are limited.

148 ced by the dramatic therapeutic responses in Crohn's disease (CD) patients induced by chimeric anti-T

149 Crohn's disease (CD) patients suffer postprandial aversi

150 d in cognitive and affective functions among Crohn's disease (CD) patients.

151 erative time has been recently developed for Crohn's disease (CD) patients.

152 thin the heterogeneous spectrum of pediatric Crohn's disease (CD) should improve patient management a

153 sitic infestations have a lower incidence of Crohn's disease (CD) than nonendemic countries, and ther

154 ostoperative disease course of patients with Crohn's disease (CD) who have undergone ileocecal resect

155 ned intestinal tissues from 92 patients with Crohn's disease (CD), 48 patients with ulcerative coliti

156 commended for children with mild to moderate Crohn's disease (CD), but implementation is challenging.

157 stinal permeability has been associated with Crohn's disease (CD), but it is not clear whether it is

158 s the only established dietary treatment for Crohn's disease (CD), but its acceptability is limited.

159 had little impact on intestinal fibrosis in Crohn's disease (CD), increased understanding of the pat

160 ts were grouped based on ultimate diagnosis: Crohn's disease (CD), Irritable bowel syndrome (IBS), NS

161 an effective therapy for moderate to severe Crohn's disease (CD), its effects on the microscopic man

162 hronic inflammatory diseases like psoriasis, Crohn's disease (CD), multiple sclerosis (MS), rheumatoi

163 associated with systemic sclerosis (SSc) and Crohn's disease (CD), some of which confer susceptibilit

164 ated the common genetic basis between CC and Crohn's disease (CD), ulcerative colitis (UC), and celia

165 rs influencing intestinal ACE2 expression in Crohn's disease (CD), ulcerative colitis (UC), and non-i

166 patients with UC compared with patients with Crohn's disease (CD)-associated colitis or without infla

167 dysbiosis and pathobiont expansion, notably Crohn's disease (CD).

168 linical remission in pediatric patients with Crohn's disease (CD).

169 be an important factor in the progression of Crohn's disease (CD).

170 ssment of perianal fistulas in patients with Crohn's disease (CD).

171 ic and histologic remission in patients with Crohn's disease (CD).

172 tests that are used to assess patients with Crohn's Disease (CD).

173 ty continuous training (MICT)-in adults with Crohn's disease (CD).

174 bserved in pediatric and adult patients with Crohn's disease (CD).

175 erianal fistulas are common in patients with Crohn's disease (CD).

176 e treatment of moderately to severely active Crohn's disease (CD).

177 her IFNL might contribute to pathogenesis of Crohn's disease (CD).

178 ese associate with outcomes of patients with Crohn's disease (CD).

179 a cytokine implicated in the pathogenesis of Crohn's disease (CD).

180 (sub)obstruction is a common complication of Crohn's disease (CD).

181 induce remission in patients with pediatric Crohn's disease (CD).

182 itor, in a randomized trial of patients with Crohn's disease (CD).

183 ue are commonly reported among patients with Crohn's disease (CD).

184 elate their association with the activity of Crohn's disease (CD).

185 of patients with ulcerative colitis (UC) vs Crohn's disease (CD).

186 inflamed and non-inflamed colonic mucosa [50 Crohn's disease (CD); 80 ulcerative colitis (UC); 31 con

187 ining environmental factors and risk of IBD (Crohn's disease [CD] or ulcerative colitis [UC]).

188 Twenty-four patients with IBD (11 with Crohn's disease [CD], 13 with ulcerative colitis [UC], m

189 (211 with ulcerative colitis [UC], 234 with Crohn's disease [CD]; 236 male), enrolled in Germany fro

190 inflammatory bowel disease(IBD) particularly Crohn's disease(CD), where associations with high and lo

191 barrier are associated with diseases such as Crohn's disease, colitis, and colon cancer, but mechanis

192 rofiles of CD8(+) T cells from children with Crohn's disease correlated with age but not with disease

193 uggest that the inflammatory milieu found in Crohn's disease could lead to or result from deregulatio

194 Most CpG methylation changes associated with Crohn's disease disappeared with treatment of inflammati

195 ulcers in the ileum or colon, or both, and a Crohn's Disease Endoscopic Index of Severity (CDEIS) of

196 ctivity on colonoscopy was measured with the Crohn's Disease Endoscopic Index of Severity (CDEIS).

197 we compare scRNA-seq profiles from pediatric Crohn's disease epithelium alongside matched healthy con

198 e of CD, analyzing results from the Food and Crohn's Disease Exacerbation Study (FACES) trial.

199 ts from pyroptosis and gut inflammation in a Crohn's disease experimental mouse model.

200 s were aged 18-75 years, with a diagnosis of Crohn's disease for at least 3 months, assessed as moder

201 genetic risk scores (GRSs) in distinguishing Crohn's disease from healthy samples, but also serve to

202 atients with ulcerative colitis and inactive Crohn's disease have lower levels of CRT, which might co

203 ease progression compared with patients with Crohn's disease (HR, 1.56; P < .001) or no IBD (HR, 1.15

204 nical benefits of cytokine blockade in ileal Crohn's disease (iCD) are limited to a subset of patient

205 the analyses of microbiomes of patients with Crohn's disease identifies 52 host and 136 microbial pro

206 n subjects with active ulcerative colitis or Crohn's disease, implicating the loss of this barrier-pr

207 we provide a physician-oriented overview of Crohn's disease in adults, ranging from epidemiology and

208 Evidence-based medical treatment of Crohn's disease in children is recommended, with thoroug

209 de guidance for medical treatment of luminal Crohn's disease in children.

210 gene Atg16L1 that confers increased risk for Crohn's disease in humans.

211 egy designed to predict the future course of Crohn's disease in patients with quiescent disease.

212 nduction of TNFalpha, ultimately aggravating Crohn's disease in the AGLCD patient, which can be rever

213 the decreased association of rs10065172 with Crohn's disease in those populations.

214 factors have been implicated in the cause of Crohn's disease, including a dysregulated immune system,

215 ceptibility variants for ulcerative colitis, Crohn's disease, inflammatory bowel disease, celiac dise

216 an 18 years with quiescent (for 3-24 months) Crohn's disease involving the small bowel with confirmed

217 In patients with quiescent Crohn's disease involving the small bowel, faecal calpro

218 Crohn's disease is a chronic inflammatory disease of the

219 Crohn's disease is a complex disease, and treatment shou

220 Crohn's disease is a relapsing and remitting inflammator

221 Crohn's disease is an inflammatory bowel disease that is

222 ophagy in intestinal defense and suggest why Crohn's disease is associated with genetic mutations tha

223 Pediatric Crohn's disease is characterized by a higher incidence o

224 r1 displayed mucosal dysfunction and induced Crohn's disease-like ileitis following transfer into Rag

225 male SAMP/YitFC mice, a spontaneous model of Crohn's disease-like ileitis.

226 analysis included 329 participants; 168 with Crohn's disease (median sCDAI score 93 [IQR 47-156]), an

227 Crohn's disease might result from a complex interplay be

228 We assessed the ability of the different Crohn's disease monitoring methods used to predict the o

229 ylation profiles at the time of diagnosis of Crohn's disease more closely resembled patterns observed

230 th numerous immunological diseases including Crohn's disease, multiple sclerosis, chronic lymphocytic

231 = 147), rheumatoid arthritis (RA, n = 229), Crohn's disease (n = 148), or ulcerative colitis (n = 36

232 from patients archived before a diagnosis of Crohn's disease (n = 200) or ulcerative colitis (n = 199

233 patients with ulcerative colitis (n = 4671), Crohn's disease (n = 3780), and IBD unclassified (n = 99

234 analyses of colon tissues from patients with Crohn's disease (n = 61) or ulcerative colitis (UC, n =

235 Nineteen cases were identified: Crohn's disease (n = 8; 42%) and juvenile idiopathic art

236 Nineteen cases were identified; Crohn's disease (n=8;42%) and juvenile idiopathic arthri

237 he systematic review, ulcerative colitis and Crohn's disease needed to be reported separately.

238 Unlike in Crohn's disease, no significant differences were found i

239 icion and capsule severity are predictive of Crohn's disease on initial CE.

240 le-blind trial of 52 patients with quiescent Crohn's disease or ulcerative colitis and persistent gut

241 ed from control individuals vs patients with Crohn's disease or ulcerative colitis did not differ sig

242 Patients with Crohn's disease or ulcerative colitis have relatively hi

243 and colon biopsy samples from patients with Crohn's disease or ulcerative colitis or healthy individ

244 d from healthy individuals and patients with Crohn's disease or ulcerative colitis secreted IL22, whi

245 stations have been reported in patients with Crohn's disease or ulcerative colitis.

246 Most studies evaluated adults with Crohn's disease or ulcerative colitis.

247 in patients with gastrointestinal bleeding, Crohn's disease, or celiac disease, who have had negativ

248 hepatitis C, psoriasis, psoriatic arthritis, Crohn's disease, or ulcerative colitis and who were in c

249 uding asthma, breast cancer, celiac disease, Crohn's disease, Parkinson's disease and type 2 diabetes

250 arnelian's effectiveness on type 2 diabetes, Crohn's disease, Parkinson's disease, and industrialized

251 actor with an established regulatory role in Crohn's disease pathogenesis.

252 s largely through CARD9 and is recognized by Crohn's disease patient anti-fungal antibodies.

253 ulcerative colitis patients when compared to Crohn's disease patients (27% vs. 5%, P < 0.001) within

254 ApoA1 expression, which is downregulated in Crohn's disease patients and causally linked to colitis

255 the intestinal mucosa in healthy people and Crohn's disease patients and identified fungi specifical

256 ebsiella strains isolated from the saliva of Crohn's disease patients can induce Th1 cell responses t

257 The present work recruited 20 Crohn's disease patients in remission (CDs) and 20 age-g

258 sense is increased in Treg and Th17-cells of Crohn's disease patients over controls.

259 ient was compared to healthy individuals and Crohn's disease patients regarding immune cell compositi

260 nal CD14(+)CD11c(+) macrophages and mucus of Crohn's disease patients were separated into different c

261 In the intestine of Crohn's disease patients, CD14(+)CD11(+)CD163(low) macro

262 In ilea of Crohn's disease patients, increased expression of IDO1 c

263 in intestinal CD14(+)CD11c(+) macrophages of Crohn's disease patients.

264 l markers in ilea of healthy individuals and Crohn's disease patients.

265 to address severe and extensive small bowel Crohn's disease presenting with 3 severely fibrotic and

266 In re-analysis of a study of Crohn's disease prognosis, four regions remain associate

267 vious medical and drug history, and previous Crohn's disease-related surgeries were recorded at basel

268 ng its immune-stimulatory potential in human Crohn's disease remains sparse.

269 ng strategy for predicting disease course in Crohn's disease remains undefined.

270 f these findings, our study of patients with Crohn's disease revealed significantly reduced frequenci

271 of the patient's sister, also diagnosed with Crohn's disease, revealed identical variants.

272 sease (rg = 0.12 +/- 0.03, P = 2.49 x 10-4), Crohn's disease (rg = 0.097 +/- 0.06, P = 3.27 x 10-3),

273 Neutrophils from patients with acute Crohn's disease, rheumatoid arthritis, or sepsis were su

274 The Crohn's disease risk allele ATG16L1 T300A results in abn

275 cohort of 1240 biologic-naive patients with Crohn's disease starting infliximab or adalimumab therap

276 The personalised anti-TNF therapy in Crohn's disease study (PANTS) is a prospective observati

277 be critical for signaling downstream of the Crohn's disease susceptibility protein nucleotide-bindin

278 lonality in systemic lupus erythematosus and Crohn's disease that was dominated by the IgA isotype, t

279 In Crohn's disease, the characteristic expansion of mesente

280 In Crohn's disease, the DII was positively associated with

281 of developing the inflammatory bowel disease Crohn's disease, thus suggesting that the loss of the im

282 asuring plasma thymidine levels in suspected Crohn's disease to rule out MNGIE, particularly if white

283 edictions from genes known to be involved in Crohn's disease, to genes that are not known to have an

284 umans, gut microbiota density was reduced in Crohn's disease, ulcerative colitis, and ileal pouch-ana

285 atients were 17 years old or younger and had Crohn's disease, ulcerative colitis, or IBD-unclassified

286 Defined as a diagnosis of Crohn's disease, ulcerative colitis, or inflammatory bow

287 s1734907 modulates risk of schizophrenia and Crohn's disease via altered methylation and expression o

288 on profiles of DNA collected at diagnosis of Crohn's disease vs during the follow-up period showed th

289 istory of CRC, and ulcerative colitis versus Crohn's disease was considered moderate.

290 matory bowel diseases ulcerative colitis and Crohn's disease, we sequenced the whole genomes of 4,280

291 E mediated gastrointestinal food allergy and Crohn's disease, we tested whether therapeutic feeds eff

292 ere up-regulated in serum from patients with Crohn's disease were identified based on changes in prot

293 articipants with irritable bowel syndrome or Crohn's disease were more likely to have continued sympt

294 A total of 193 patients (57% female and 64% Crohn's disease) were included, with a median daily TG d

295 rity study, we enrolled patients with active Crohn's disease who had not responded to, or were intole

296 outcomes in patients with moderate to severe Crohn's disease who were managed with a tight control al

297 non-inferior to infliximab in patients with Crohn's disease who were naive to biological therapy.

298 An unusual onset of Crohn's disease with multiple splenic nodules is reporte

299 1 protein biomarkers that were predictive of Crohn's disease within 5 years with an AUROC of 0.76 and

300 of patients who will receive a diagnosis of Crohn's disease within 5 years with high accuracy.